<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7396720\results\search\disease\results.xml">
  <result pre="Pharmacologica Sinica1671-40831745-7254Springer SingaporeSingapore pmcid: 7396720485 doi: 10.1038/s41401-020-0485-4 : Review Article" exact="Structural" post="and functional properties of SARS-CoV-2 spike protein: potential antivirus"/>
  <result pre="University, [2], 0000 0000 8877 7471grid.284723.8State Key Laboratory of Organ" exact="Failure" post="Research, Southern Medical University, epub: 2020-8-819received: 2020-5-15accepted: 2020-7-15(C) ,"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 is a newly emerging infectious disease currently spreading"/>
  <result pre="global pandemic. Abstract Coronavirus disease 2019 is a newly emerging" exact="infectious disease" post="currently spreading across the world. It is caused by"/>
  <result pre="pandemic. Abstract Coronavirus disease 2019 is a newly emerging infectious" exact="disease" post="currently spreading across the world. It is caused by"/>
  <result pre="the world. It is caused by a novel coronavirus, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). The spike (S) protein"/>
  <result pre="world. It is caused by a novel coronavirus, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). The spike (S) protein of"/>
  <result pre="It is caused by a novel coronavirus, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). The spike (S) protein of SARS-CoV-2,"/>
  <result pre="host receptor angiotensin-converting enzyme 2, while the S2 subunit mediates" exact="viral" post="cell membrane fusion by forming a six-helical bundle via"/>
  <result pre="inhibitors; host proteases inhibitors Introduction The epidemic of novel coronavirus" exact="disease" post="2019 (COVID-19) was caused by a new coronavirus occurred"/>
  <result pre="discovered to be caused by a coronavirus later named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], which belongs to"/>
  <result pre="to be caused by a coronavirus later named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) [1], which belongs to the"/>
  <result pre="be caused by a coronavirus later named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) [1], which belongs to the Î²"/>
  <result pre="to the host cell receptor angiotensin-converting enzyme 2 (ACE2), mediating" exact="viral" post="cell entry [8]. When the S protein binds to"/>
  <result pre="binds to the receptor, TM protease serine 2 (TMPRSS2), a" exact="type 2" post="TM serine protease located on the host cell membrane,"/>
  <result pre="the S protein. Once the virus enters the cell, the" exact="viral" post="RNA is released, polyproteins are translated from the RNA"/>
  <result pre="from the RNA genome, and replication and transcription of the" exact="viral" post="RNA genome occur via protein cleavage and assembly of"/>
  <result pre="occur via protein cleavage and assembly of the replicaseâ€&quot;transcriptase complex." exact="Viral" post="RNA is replicated, and structural proteins are synthesized, assembled,"/>
  <result pre="synthesized, assembled, and packaged in the host cell, after which" exact="viral" post="particles are released (Fig. 1d) [9]. Fig. 1 Schematic"/>
  <result pre="SARS-CoV-2 in host cells. These proteins are critical to the" exact="viral" post="life cycle and provide potential targets for drug therapies."/>
  <result pre="all human coronaviruses (HCoVs) and is involved in receptor recognition," exact="viral" post="attachment, and entry into host cells. Due to its"/>
  <result pre="an extracellular N-terminus, a transmembrane (TM) domain anchored in the" exact="viral" post="membrane, and a short intracellular C-terminal segment [11]. S"/>
  <result pre="transmembrane (TM) domain anchored in the viral membrane, and a" exact="short" post="intracellular C-terminal segment [11]. S normally exists in a"/>
  <result pre="surveillance of the host immune system during entry [12]. The" exact="total" post="length of SARS-CoV-2 S is 1273 aa and consists"/>
  <result pre="trimers visually form a characteristic bulbous, crown-like halo surrounding the" exact="viral" post="particle (Fig.Â 1a). Based on the structure of coronavirus"/>
  <result pre="the CoV S protein exists as an inactive precursor. During" exact="viral infection," post="target cell proteases activate the S protein by cleaving"/>
  <result pre="which is necessary for activating the membrane fusion domain after" exact="viral" post="entry into target cells [18]. Similar to other coronaviruses,"/>
  <result pre="the surface of the host cell is the initiation of" exact="virus infection;" post="therefore, receptor recognition is an important determinant of viral"/>
  <result pre="virus infection; therefore, receptor recognition is an important determinant of" exact="viral" post="entry and a drug design target. RBD situated in"/>
  <result pre="SARS-CoV-2 [20]. Similarly, a SARS-CoV RBD-specific antibody failed to block" exact="infection" post="mediated by the S protein of SL-CoVâ€&quot;SHC014 [22], which"/>
  <result pre="TM domain, and cytoplasmic domain fusion (CT), is responsible for" exact="viral" post="fusion and entry. FP is a short segment of"/>
  <result pre="is responsible for viral fusion and entry. FP is a" exact="short" post="segment of 15â€&quot;20 conserved amino acids of the viral"/>
  <result pre="a short segment of 15â€&quot;20 conserved amino acids of the" exact="viral" post="family, composed mainly of hydrophobic residues, such as glycine"/>
  <result pre="six-helical bundle (6-HB) (Fig.Â 2e), which is essential for the" exact="viral" post="fusion and entry function of the S2 subunit [13]."/>
  <result pre="The downstream TM domain anchors the S protein to the" exact="viral" post="membrane, and the S2 subunit ends in a CT"/>
  <result pre="domain and HR1 trimer to form 6-HB, thus bringing the" exact="viral" post="envelope and cell membrane into proximity for viral fusion"/>
  <result pre="bringing the viral envelope and cell membrane into proximity for" exact="viral" post="fusion and entry [26]. HR1 forms a homotrimeric assembly"/>
  <result pre="of the S2 subunit plays an essential role in HCoV" exact="infections" post="and is conserved among HCoVs, as is the mode"/>
  <result pre="ZIKV envelope protein was demonstrated in 2017 to potently inhibit" exact="infection" post="byÂ ZIKV and other flaviviruses in vitro [29], implying"/>
  <result pre="implying antiviral efficiency of peptides derived from conserved regions of" exact="viral" post="proteins. Peptides derived from the HR2 region of class"/>
  <result pre="proteins. Peptides derived from the HR2 region of class I" exact="viral" post="fusion proteins of enveloped viruses competitively bind to viral"/>
  <result pre="I viral fusion proteins of enveloped viruses competitively bind to" exact="viral" post="HR1 and effectively inhibit viral infection [22]. Therefore, HR1"/>
  <result pre="enveloped viruses competitively bind to viral HR1 and effectively inhibit" exact="viral infection" post="[22]. Therefore, HR1 is a promising target for the"/>
  <result pre="viruses competitively bind to viral HR1 and effectively inhibit viral" exact="infection" post="[22]. Therefore, HR1 is a promising target for the"/>
  <result pre="It is a trimeric class I TM glycoprotein responsible for" exact="viral" post="entry, and it is present in all kinds of"/>
  <result pre="of SARS-CoV-2 mediates receptor recognition, cell attachment, and fusion during" exact="viral infection" post="[16, 20, 21, 31â€&quot;33]. The trimer of the S"/>
  <result pre="SARS-CoV-2 mediates receptor recognition, cell attachment, and fusion during viral" exact="infection" post="[16, 20, 21, 31â€&quot;33]. The trimer of the S"/>
  <result pre="of the S protein located on the surface of the" exact="viral" post="envelope is the basic unit by which the S"/>
  <result pre="mainly in the lung, intestine, heart, and kidney, and alveolar" exact="epithelial" post="type II cells are the major expressing cells [36]."/>
  <result pre="in the lung, intestine, heart, and kidney, and alveolar epithelial" exact="type II" post="cells are the major expressing cells [36]. ACE2 is"/>
  <result pre="with ACE2 to promote the formation of endosomes, which triggers" exact="viral" post="fusion activity under low pH (Fig. 1a, b) [37]."/>
  <result pre="the S protein and ACE2 can be used to identify" exact="intermediate" post="hosts of SARS-CoV-2, as ACE2 from different species, such"/>
  <result pre="species, such as amphibians, birds, and mammals, has a conserved" exact="primary" post="structure [38]. Luan et al. compared the binding affinities"/>
  <result pre="ACE2 through the RBD region of the S1 subunit, mediating" exact="viral" post="attachment to host cells in the form of a"/>
  <result pre="SARS-CoV-2 and SARS-CoV, whereas that of RBD is ~23% [39]." exact="Viral" post="fusion Viral fusion refers to fusion of the viral"/>
  <result pre="SARS-CoV, whereas that of RBD is ~23% [39]. Viral fusion" exact="Viral" post="fusion refers to fusion of the viral membrane and"/>
  <result pre="[39]. Viral fusion Viral fusion refers to fusion of the" exact="viral" post="membrane and host cell membrane, resulting in the release"/>
  <result pre="and host cell membrane, resulting in the release of the" exact="viral" post="genome into the host cell. Cleavage of the SARS-CoV-2"/>
  <result pre="proteases, and the subunits exist in a noncovalent form until" exact="viral" post="fusion occurs [40]. Researchers have found that the specific"/>
  <result pre="and is related to its pathogenicity, as observed in the" exact="avian influenza" post="outbreak in Hong Kong in 1997 [45, 46]. In"/>
  <result pre="Another host cell protease that has been proven to cleave" exact="viral" post="S protein is trypsin [49]. In summary, the S"/>
  <result pre="contagious than SARS-CoV. The formation of 6-HB is essential for" exact="viral" post="fusion. The FP in the N-terminus of SARS-CoV-2 and"/>
  <result pre="and the two HR domains on S2 is essential for" exact="viral" post="fusion [50]. After cleavage of the S protein, the"/>
  <result pre="S protein, the FP of SARS-CoV-2 is exposed and triggers" exact="viral" post="fusion. Under the action of some special ligands, the"/>
  <result pre="such as CCR5 or CXCR4 [14]. The distance between the" exact="viral" post="membrane and host cell membrane is shortened, and the"/>
  <result pre="cell membrane, whereas the HR2 domain is closer to the" exact="viral" post="membrane side. Then, HR2 folds back to HR1, the"/>
  <result pre="structure in an antiparallel format of the fusion core, the" exact="viral" post="membrane is pulled toward the host cell membrane and"/>
  <result pre="S protein The fundamental role of the S protein in" exact="viral infection" post="indicates that it is a potential target for vaccine"/>
  <result pre="protein The fundamental role of the S protein in viral" exact="infection" post="indicates that it is a potential target for vaccine"/>
  <result pre="nAbs targeting the S protein can induce protective immunity against" exact="viral infection." post="Similar to SARS-CoV and MERS-CoV, research on nAbs of"/>
  <result pre="SARS-CoV-2 vaccine types are under development, including RNA/DNA-based formulations, recombinant" exact="viral" post="epitopes, adenovirus-based vectors, and purified inactivated virus [55]. The"/>
  <result pre="immunized mice completely inhibited the invasion of SARS-CoV S-MLV (murine" exact="leukemia" post="virus), whereas the invasion rate of SARS-CoV-2 S-MLV was"/>
  <result pre="with other nAbs, for the prevention and treatment of SARS-CoV-2" exact="infection" post="[57]. A mAb targeting S1 prepared from immunized transgenic"/>
  <result pre="has recently been shown to neutralize both SARS-CoV-2 and SARS-CoV" exact="infections" post="via an unknown mechanism that is independent of the"/>
  <result pre="Fusion inhibitors The stability of the SARS-CoV-2 S protein is" exact="lower" post="than that of SARS-CoV S [42]. The mapping of"/>
  <result pre="and that the S1 subunit is more exposed at the" exact="viral" post="surface [16]. The SARS-CoV S2 subunit plays a key"/>
  <result pre="IPB02, potently inhibits SARS-CoV-2 S protein-mediated cellâ€&quot;cell fusion and pseudovirus" exact="infection" post="[65]. In addition to peptide fusion inhibitors, nelfinavir mesylate"/>
  <result pre="entry via endocytosis. E-64d, an inhibitor of cathepsin L, blocks" exact="infection" post="with SARS-CoV and SARS-CoV-2 PsV [68â€&quot;70]. Future trials with"/>
  <result pre="the S protein of SARS-CoV-2 may have implications for the" exact="viral" post="life cycle and pathogenicity. Therefore, furin inhibitors can be"/>
  <result pre="can be used as a drug therapy for SARS-CoV-2 [41]." exact="Patent" post="literature since 1994 describes the use of furin or"/>
  <result pre="support the discovery of antiviral therapeutics and precision vaccine design." exact="Structural" post="information will also assist in evaluating mutations of the"/>
  <result pre="the course of virus epidemics, the ability to adapt to" exact="external" post="pressure is an important factor affecting the spread of"/>
  <result pre="has been used clinically to treat or prevent SARS-CoV-2 infection." exact="Nonspecific" post="antiviral drugs, such as IFN-Î± (recombinant human IFN-Î±1b, IFN-Î±2a),"/>
  <result pre="interests. References References 1.ZhuNZhangDWangWLiXYangBSongJet al.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med20203827273310.1056/NEJMoa200101731978945 2.WuCLiuYYangYZhangPZhongWWangYet al.Analysis of"/>
  <result pre="related human coronavirus diseasesACS Cent Sci202063153132226821 4.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA2020323182436 5.LuRZhaoXLiJNiuPYangBWuHet al.Genomic characterisation and epidemiology"/>
  <result pre="mNGS approach identifies a novel human coronavirus from two individual" exact="pneumonia" post="cases in 2019 Wuhan outbreakEmerg Microbes Infect20209313932020836 7.ChanJFKokKHZhuZChuHToKKYuanSet al.Genomic"/>
  <result pre="the 2019 novel human-pathogenic coronavirus isolated from a patient with" exact="atypical pneumonia" post="after visiting WuhanEmerg Microbes Infect202092213631987001 8.LetkoMMarziAMunsterVFunctional assessment of cell"/>
  <result pre="2019 novel human-pathogenic coronavirus isolated from a patient with atypical" exact="pneumonia" post="after visiting WuhanEmerg Microbes Infect202092213631987001 8.LetkoMMarziAMunsterVFunctional assessment of cell"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChembiochem202021730832022370 11.BoschBJvan der ZeeRde HaanCARottierPJThe"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChembiochem202021730832022370 11.BoschBJvan der ZeeRde HaanCARottierPJThe coronavirus"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChembiochem202021730832022370 11.BoschBJvan der ZeeRde HaanCARottierPJThe coronavirus spike"/>
  <result pre="229E for cathepsin-independent host cell entry and is expressed in" exact="viral" post="target cells in the respiratory epitheliumJ Virol20138761506023536651 18.HoffmannMKleine-WeberHSchroederSKrugerNHerrlerTErichsenSet al.SARS-CoV-2"/>
  <result pre="entry and is expressed in viral target cells in the" exact="respiratory" post="epitheliumJ Virol20138761506023536651 18.HoffmannMKleine-WeberHSchroederSKrugerNHerrlerTErichsenSet al.SARS-CoV-2 cell entry depends on ACE2"/>
  <result pre="of SARS coronavirus by protease factor Xa is associated with" exact="viral" post="infectivityBiochem Biophys Res Commun2007359174917533109 20.WangQZhangYWuLNiuSSongCZhangZet al.Structural and functional basis"/>
  <result pre="several types of virus fusion glycoproteinsJ Gen Virol1990713075802177097 25.RobsonBComputers and" exact="viral" post="diseases. Preliminary bioinformatics studies on the design of a"/>
  <result pre="fusogenic mechanism and identification of fusion inhibitorsLancet20043639384715043961 29.YuYDengYQZouPWangQDaiYYuFet al.A peptide-based" exact="viral" post="inactivator inhibits Zika virus infection in pregnant mice and"/>
  <result pre="of fusion inhibitorsLancet20043639384715043961 29.YuYDengYQZouPWangQDaiYYuFet al.A peptide-based viral inactivator inhibits Zika" exact="virus infection" post="in pregnant mice and fetusesNat Commun201781567228742068 30.WeissenhornWDessenACalderLJHarrisonSCSkehelJJWileyDCStructural basis for"/>
  <result pre="fusion inhibitorsLancet20043639384715043961 29.YuYDengYQZouPWangQDaiYYuFet al.A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetusesNat Commun201781567228742068 30.WeissenhornWDessenACalderLJHarrisonSCSkehelJJWileyDCStructural basis for"/>
  <result pre="al.Human influenza A H5N1 virus related to a highly pathogenic" exact="avian influenza" post="virusLancet199835147279482438 46.KidoHOkumuraYTakahashiEPanHYWangSYaoDet al.Role of host cellular proteases in the"/>
  <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike proteinJ Virol201488129330724227843 48.LimburgHHarbigABestleDSteinDAMoultonHMJaegerJet al.TMPRSS2 is"/>
  <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike proteinJ Virol201488129330724227843 48.LimburgHHarbigABestleDSteinDAMoultonHMJaegerJet al.TMPRSS2 is the"/>
  <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike proteinJ Virol201488129330724227843 48.LimburgHHarbigABestleDSteinDAMoultonHMJaegerJet al.TMPRSS2 is the major"/>
  <result pre="is the major activating protease of influenza A virus in" exact="primary" post="human airway cells and influenza B virus in human"/>
  <result pre="primary human airway cells and influenza B virus in human" exact="type II" post="pneumocytesJ Virol201993e006491931391268 49.OuXLiuYLeiXLiPMiDRenLet al.Characterization of spike glycoprotein of SARS-CoV-2"/>
  <result pre="intermediates during membrane fusionJ Virol201993e007851931315988 51.HarrisonSCViral membrane fusionVirology2015479-48049850725866377 52.EckertDMKimPSMechanisms of" exact="viral" post="membrane fusion and its inhibitionAnnu Rev Biochem20017077781011395423 53.DhamaKSharunKTiwariRDadarMMalikYSSinghKPet al.COVID-19,"/>
  <result pre="Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al." exact="Structural" post="and functional analysis of a potent sarbecovirus neutralizing antibody."/>
  <result pre="vulnerability. bioRxiv. 2020. 10.1101/2020.05.08.083964. 64.XiaSLiuMQWangCXuWLanQSFengSLet al.Inhibition of SARS-CoV-2 (previously 2019-nCoV)" exact="infection" post="by a highly potent pan-coronavirus fusion inhibitor targeting its"/>
  <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res201722871327840112 69.HuangICBoschBJLiWHFarzanMRottierPMChoe H. SARS-CoV, but"/>
  <result pre="endosome/lysosome and block the entry of Ebola virus, Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus"/>
  <result pre="and block the entry of Ebola virus, Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)J"/>
  <result pre="Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV)J Biol Chem201629192183226953343 71.NelsonEADyallJHoenenTBarnesABZhouHLiangJYet al.The phosphatidylinositol-3-phosphate"/>
  <result pre="virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV)J Biol Chem201629192183226953343 71.NelsonEADyallJHoenenTBarnesABZhouHLiangJYet al.The phosphatidylinositol-3-phosphate 5-kinase"/>
  <result pre="Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV)J Biol Chem201629192183226953343 71.NelsonEADyallJHoenenTBarnesABZhouHLiangJYet al.The phosphatidylinositol-3-phosphate 5-kinase inhibitor"/>
  <result pre="Dis201711e000554028403145 72.HouJZXiZQNiuJLiWWangXLiangCet al.Inhibition of PIKfyve using YM201636 suppresses the growth" exact="of liver" post="cancer via the induction of autophagyOncol Rep2019411971930569119 73.SakuraiYKolokoltsovAAChenCCTidwellMWBautaWEKlugbauerNet al.Two-pore"/>
  <result pre="72.HouJZXiZQNiuJLiWWangXLiangCet al.Inhibition of PIKfyve using YM201636 suppresses the growth of" exact="liver cancer" post="via the induction of autophagyOncol Rep2019411971930569119 73.SakuraiYKolokoltsovAAChenCCTidwellMWBautaWEKlugbauerNet al.Two-pore channels"/>
  <result pre="al.Inhibition of PIKfyve using YM201636 suppresses the growth of liver" exact="cancer" post="via the induction of autophagyOncol Rep2019411971930569119 73.SakuraiYKolokoltsovAAChenCCTidwellMWBautaWEKlugbauerNet al.Two-pore channels"/>
  <result pre="Ebola virus host cell entry and are drug targets for" exact="disease" post="treatmentScience2015347995825722412 74.ArtensteinAWOpalSMProprotein convertases in health and diseaseN Engl J"/>
  <result pre="2019 novel coronavirus in Wuhan, ChinaLancet202039549750631986264 76.YakalaGKCabrera-FuentesHACrespo-AvilanGERattanasopaCBurlacuAGeorgeBLet al.FURIN inhibition reduces" exact="vascular remodeling" post="and atherosclerotic lesion progression in miceArterioscler Thromb Vasc Biol20193938740130651003"/>
  <result pre="with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic" exact="avian influenza" post="viruses and delays high level oseltamivir resistance in MDCK"/>
  <result pre="level oseltamivir resistance in MDCK cellsAntivir Res20151208910026022200 80.AbidinAZDSouzaAMNagarajanMBWangLQiuXSchifittoGet al.Alteration of" exact="brain" post="network topology in HIV-associated neurocognitive disorder: a novel functional"/>
  <result pre="reference sequence for SARS-CoV-2 and variation analysisJ Med Virol2020926677432167180 82.Becerra-FloresMCardozoTSARS-CoV-2" exact="viral" post="spike G614 mutation exhibits higher case fatality rateInt J"/>
 </snippets>
</snippetsTree>
